The growing emphasis on CLD is evident in market projections. The global cell line development market is expected to expand ...

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on ...

This hematopoietic gene therapy offers a new treatment for children with severe leukocyte adhesion deficiency-I without matched transplant donors.

Rocket Pharmaceuticals (NASDAQ:RCKT) said the U.S. Food and Drug Administration has granted accelerated approval to KRESLADI ...

Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 March 27, 2026 8:30 ...

A phase 1/2 trial of a novel viral vector gene therapy in adults with type 1 diabetes is scheduled to begin this year.

The notorious disease known as sleeping sickness can lurk inside a host for months or even years before serious symptoms ...

Kids with severe LAD-I, caused by ITGB2 mutations, are at risk of life-threatenin ...

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Formula 1 sells itself as a calendar, but it actually runs on a graph. Not the pretty Gantt chart you see at the season ...

Block's restructuring and a co-authored essay with Sequoia's Roelof Botha give VCs a concrete blueprint for the AI-native ...

Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA ...